Policy
Latest Content
AstraZeneca’s Speke U-turn deals blow to Government’s life sciences ambition
AstraZeneca’s shock reversal of its plans to expand vaccine manufacturing at its Speke plant on Merseyside has put an end to hopes of the proposed £450 million investment in the site.
News
AstraZeneca’s Speke U-turn deals blow to Government’s life sciences ambition
AstraZeneca’s shock reversal of its plans to expand vaccine manufacturing at its Speke plant on Merseyside has put an end to hopes of the proposed £450 million investment in the site.
In Depth
Enabling miniaturisations of automated organoid drug screens
Advanced cell-based models have grown in popularity for drug testing applications. The use of nanofibrillar cellulose hydrogels has enabled organoid drug screening that is largely animal free, automa…
Comment And Analysis
The Future of Lab Informatics
What will 2025 bring in terms of lab informatics? How will advanced technologies drive new discoveries? Jonathan Gross of Labguru provides some answers…
Interviews
Making tough choices digestible
“To eat is to compete in an arms race,” says Dr Chris van Tulleken, whose thoughts on evangelising through science, engaging food producers and self-experimentation promise another absorbing series o…
